Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.50 |
| ▸ | ALPL | P05186 | 2/20 | 0.45 |
| ▸ | ACLY | P53396 | 2/20 | 0.43 |
| ▸ | CCR2 | P41597 | 4/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948966 | 0.84 | TRPV4 (0.53) | TRPV4CCR2ALDH1A1L3MBTL1 | |
| SCHEMBL1029355 | 0.84 | TRPV4 (0.53) | TRPV4CCR2ALDH1A1L3MBTL1 | |
| SCHEMBL574988 | 0.82 | PKM (0.47) | TRPV4ACLYCCR2 | |
| SCHEMBL29536851 | 0.82 | PKM (0.47) | TRPV4ACLYCCR2 | |
| SCHEMBL11158206 | 0.82 | ALPL (0.45) | TRPV4ALPLACLYCCR2MCL1 | |
| SCHEMBL3649176 | 0.82 | KDM4E (0.45) | TRPV4ALPLACLYMCL1ALDH1A1 | |
| SCHEMBL1645034 | 0.80 | CA1 (0.47) | ALPLACLYCCR2CNR1 | |
| SCHEMBL4012968 | 0.80 | CCR2 (0.56) | TRPV4ALPLACLYCCR2CNR1 | |
| SCHEMBL10571424 | 0.80 | ALDH1A1 (0.39) | TRPV4ALDH1A1CNR1 | |
| SCHEMBL30762457 | 0.80 | CCR2 (0.56) | TRPV4ALPLACLYCCR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20250326770-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-10-23 | — | — | US | disclosed |
| US-12441754-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2025-10-14 | — | — | US | disclosed |
| US-20250282724-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-09-11 | — | — | US | disclosed |
| US-12378260-B2 | Benzotriazole compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-08-05 | — | — | US | disclosed |
| US-20250092064-A1 | BENZOTRIAZOLE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-4509504-A1 | BENZOTRIAZOLE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2025-02-19 | — | — | EP | disclosed |
| CN-119173511-A | Benzotriazole compounds | 第一三共株式会社 | 2024-12-20 | — | — | CN | disclosed |
| EP-3498693-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-30 | — | — | EP | disclosed |
| EP-1797042-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006034804-A1 | INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-03-30 | — | — | US | disclosed |
| EP-1610753-A2 | PHENYLENEDIAMINE UROTENSIN-II RECEPTOR ANTAGONISTS AND CCR-9 ANTAGONISTS | ENCYSIVE PHARMACEUTICALS INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1597259-A1 | NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO 1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20050085483-A1 | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2005-03-03 | — | — | US | disclosed |
| US-20040180892-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | ENCYSIVE PHARMACEUTICALS INC. | 2004-09-16 | — | — | US | disclosed |
| WO-2004073634-A2 | PHENYLENEDIAMINE UROTENSIN-II RECEPTOR ANTAGONISTS AND CCR-9 ANTAGONISTS | ENCYSIVE PHARMACEUTICALS INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004072077-A1 | NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO[1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049286-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | TRPV4 831/4885ALPL 4840/4885ACLY 4820/4885 |
| US-20250092064-A1 | BENZOTRIAZOLE COMPOUND | NFE2L2, BPTF, KEAP1 | TRPV4 2544/4885ALPL 4252/4885ACLY 3851/4885 |
| US-20040180892-A1 | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists | CCR9, CCR1, CCRL2 | TRPV4 831/4885ALPL 4840/4885ACLY 4820/4885 |
| US-12378260-B2 | Benzotriazole compound | NFE2L2, BPTF, KEAP1 | TRPV4 2544/4885ALPL 4252/4885ACLY 3851/4885 |
| US-20050085483-A1 | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | DPYD, NUDT1, NT5C2 | TRPV4 322/4885ALPL 1364/4885ACLY 1781/4885 |
| US-20250326770-A1 | BENZOTRIAZOLE COMPOUND | KEAP1, NFE2L2, TXNRD2 | TRPV4 3953/4885ALPL 4201/4885ACLY 3693/4885 |
| US-12441754-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | TRPV4 4696/4885ALPL 2898/4885ACLY 3656/4885 |
| US-20060069269-A1 | Novel indazolone derivatives useful as 11b-HSD1 inhibitors | HSD17B1, HSD11B1, HSD17B7 | TRPV4 4103/4885ALPL 1556/4885ACLY 2238/4885 |
| US-20250282724-A1 | BENZOTRIAZOLE COMPOUND | NFE2L2, BPTF, KEAP1 | TRPV4 2544/4885ALPL 4252/4885ACLY 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.